MedaPhor Group plc

("MedaPhor" or the "Group" or the "Company")

Director and PCA Dealings

Further to the Company's announcements on 26 November 2018 and 12 December 2018, MedaPhor announces that certain Directors, persons closely associated ("PCA") with them and an employee have, following Admission today, acquired a total of 1,847,064 ordinary shares of 1 pence each in the Company ("Ordinary Shares") via the Placing:

Name	Title	Number of Placing Shares subscribed for	Value of Placing Shares subscribed for	Resulting shareholding following subscription	Percentage of enlarged share capital following subscription
Riccardo Pigliucci	Non-Executive Chairman	117,648	£ 10,000.08	117,648	0.1%
Stuart Gall	Chief Executive Officer	588,236	£ 50,000.06	628,236	0.4%
Wilson Jennings	Finance Director	294,118	£ 25,000.03	294,118	0.2%
Nicholas Sleep	Chief Technology Officer	176,471	£ 15,000.04	226,471	0.1%
Ian Whittaker	Chief Operating Officer	117,648	£ 10,000.08	349,982	0.2%
Nick Avis*	Non-Executive Director	141,177	£ 12,000.06	341,177	0.2%
Andrew Barker	Non-Executive Director	117,648	£ 10,000.08	317,992	0.2%

^{*} Nick Avis' subscription has been made via his children: Alice Avis, Florence Avis and Harriet Avis who have each subscribed for 47,059 Placing Shares. Alice, Florence and Harriet are considered to be persons closely associated with Nick Avis.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

1	Details of the person discharging managerial responsibilities / person closely associated			
a)	Name	1.	Riccardo Pigliucci	
		2.	Stuart Gall	
		3.	Wilson Jennings	
		4.	Nicholas Sleep	
		5.	Ian Whittaker	
		6.	Alice Avis	
		7.	Florence Avis	
		8.	Harriet Avis	
		9.	Andrew Barker	
2	Reason for the notification	eason for the notification		
a)	Position/status		Non-Executive Chairman	
		2.	Chief Executive Officer	
		3.	Finance Director	
		4.	Chief Technology Officer	
		5.	Chief Operating Officer	

b) 3	Initial notification /Amendment Details of the issuer, emission allowed monitor	7. Person closely associated 8. Person closely associated 9. Non-Executive Director Initial	with Nick Avis (Non-Executive Director) with Nick Avis (Non-Executive Director) with Nick Avis (Non-Executive Director) on platform, auctioneer or auction			
a)	Name	MedaPhor Group plc				
b)	LEI	213800K4ZVWL4ZYQAZ70				
4	transaction; (iii) each date; and (iv)	ion(s): section to be repeated for (i) each type of instrument; (ii) each type of date; and (iv) each place where transactions have been conducted				
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 1 pence each				
	Identification code	ISIN: GB00BN791Q39				
b)	Nature of the transaction	Purchase of Ordinary Shares				
c)	Price(s) and volume(s)	Price(s) 1. 8.5 pence 2. 8.5 pence 3. 8.5 pence 4. 8.5 pence 5. 8.5 pence 6. 8.5 pence 7. 8.5 pence 8. 8.5 pence 9. 8.5 pence	Volume(s) 1. 117,648 2. 588,236 3. 294,118 4. 176,471 5. 117,648 6. 47,059 7. 47,059 8. 47,059 9. 117,648			
d)	Aggregated information - Aggregated volume - Price	N/A – single transaction				
e)	Date of the transaction	e of the transaction 13 December 2018				
f)	Place of the transaction	London Stock Exchange, XLON				

Enquiries:

MedaPhor Group plc Stuart Gall, CEO Wilson Jennings, CFO

Cenkos Securities - Nominated Advisor and broker

Mark Connelly / Cameron MacRitchie (Corporate

Finance)

Michael Johnson / Julian Morse (Sales)

Tel: +44 (0)20 7397 8900

www.medaphor.com Tel: +44 (0)29 2075 6534

Walbrook PR

Anna Dunphy / Paul McManus

Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893